Table 1 Major characteristics of trials included in the network meta-analysis.
From: Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis
Studies | Year | ClinicalTrials.gov identifier | Number of patients | P2Y12 inhibitors | Primary endpoints | Definition of bleeding |
|---|---|---|---|---|---|---|
DISPERSE-223 | 2007 | NA | 661 | Ticagrelor (AZD6140) vs. clopidogrel | TIMI major or minor bleeding | TIMI |
PLATO8 | 2012 | NCT00391872 | 18,624 | Ticagrelor (AZD6140) vs. clopidogrel | Composite of death from vascular causes, myocardial infarction, or stroke | PLATO-defineda, TIMI |
PHILO24 | 2015 | NCT01294462 | 801 | Ticagrelor vs. clopidogrel | Composite of death from vascular causes, myocardial infarction, or stroke | PLATO-defineda |
Tang et al.25 | 2016 | NA | 400 | Ticagrelor vs. clopidogrel | Composite of overall death, myocardial infarction, unplanned revascularization, and stroke | TIMI |
SETFAST26 | 2017 | NCT01930591 | 144 | Ticagrelor vs. clopidogrel | Bleeding | BARC |
Wang et al.27 | 2016 | NA | 200 | Ticagrelor vs. clopidogrel | Composite of myocardial infarction, stroke, or cardiovascular death | PLATO-defineda |
TREAT28 | 2018 | NCT02298088 | 3799 | Ticagrelor vs. clopidogrel | Major bleeding | TIMI, PLATO-defineda, BARC |
JUMBO–TIMI 2629 | 2005 | NA | 904 | Prasugrel vs. clopidogrel | Composite of TIMI major and minor hemorrhage | TIMI |
TRILOGY ACS30 | 2012 | NCT00699998 | 7243 | Prasugrel vs. clopidogrel | Composite of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke | TIMI, GUSTO |
TRITON-TIMI 386 | 2009 | NCT00097591 | 13,608 | Prasugrel vs. clopidogrel | Composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke | TIMI |
PRASFIT-ACS31 | 2014 | NA | 1363 | Prasugrel vs. clopidogrel | Composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke | TIMI |
CHAMPION PCI10 | 2009 | NCT00305162 | 8667 | Cangrelor vs. Clopidogrel | Composite of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 h | GUSTO, TIMI, ACUITY |
CHAMPION PLATFORM11 | 2009 | NCT00385138 | 5295 | Cangrelor vs. clopidogrel | Composite of death, myocardial infarction, or ischemia-driven revascularization 48 h after percutaneous coronary intervention | TIMI, GUSTO, ACUITY |
CHAMPION PHOENIX13 | 2013 | NCT01156571 | 10,939 | Cangrelor vs. clopidogrel | Composite rate of death from any cause, myocardial infarction, ischemia-driven revascularization, or stent thrombosis in the 48 h | GUSTO, TIMI |
PRAGUE-1818 | 2017 | NCT02808767 | 1230 | Ticagrelor vs. prasugrel | Composite of cardiovascular death, non-fatal myocardial infarction, or stroke | TIMI, BARC |
ISAR-REACT 519 | 2019 | NCT01944800 | 4018 | Ticagrelor vs. prasugrel | Composite of death, myocardial infarction, or stroke | BARC |
